Consultancy: Akebia*, Bayer, and Cardurion Pharmaceuticals Grant/research support: National Institutes of Health* *Monies paid to institution. Sheldon W. Tobe, MD, FRCPC, FRCP, FACP, FAHA, MScCH (HPTE), received his medical de- gree in 1985 from the University of Calgary, Alberta, Canada. Dr. Tobe trained in internal medicine and nephrology at the University of Toronto, Ottawa, Canada. He is a professor of medicine at both the University of Toronto and the Northern Ontario School of Medicine and the Nephrology Postgraduate Fellowship Di- rector at the University of Toronto. Dr. Tobe was previously the director of the nephrology division at Sunnybrook Research Institute. His clinical activities focus on hemodialysis and patients with CKD and hypertension. His main research interests are implementation science for the dissemination of cardiovascular-focused clinical practice guidelines. Dr. Tobe was Chair of the Canadian Hypertension Education Program from 2005 to 2012 and is a Co-Chair of the Canadian Car- diovascular Harmonized National Guidelines Endeavor (C- CHANGE). He also chairs the diabetes subgroup of Hyper- tension Canada s clinical practice guidelines. Dr. Tobe serves on the Board of Directors of the American Society of Hy- pertension Specialists Program. Dr. Tobe has had continuous peer-reviewed funding for 25 years. Dr. Tobe has received many teaching awards and other career distinctions, has published over 150 peer-reviewed articles, and has led and participated in peer-reviewed, investigator-initiated, and multi-centered international research collaborations. Consultancy: AstraZeneca Grant/research support: Bayer* Speaker bureaus: AstraZeneca and Janssen *Monies paid to institution. Charles R.V. Tomson, MA, BM, Bch, DM, FRCP, received his un- dergraduate training at Cambridge and Oxford, UK, and underwent clinical training in Nottingham, Newcastle upon Tyne, and Leicester, UK, before taking up consultant posts at St Barts, Lon- 2014), and Newcastle upon Tyne (2014 2018). 